Therapy Detail

Therapy Name Tanibirumab
Synonym
Therapy Description

Tanibirumab (TTAC-0001) is a monoclonal antibody directed against KDR (VEGFR2), which may inhibit tumor angiogenesis (PMID: 21910042).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tanibirumab TTAC-0001 VEGFR2 Antibody 4 Tanibirumab (TTAC-0001) is a monoclonal antibody directed against KDR (VEGFR2), which may inhibit tumor angiogenesis (PMID: 21910042).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown breast cancer not applicable Tanibirumab Preclinical - Cell culture Actionable In a preclinical study, Tanibirumab (TTAC-0001) inhibited angiogenesis in a cell culture assay with human breast cancer cells (PMID: 26325365). 26325365
Unknown unknown colorectal cancer not applicable Tanibirumab Preclinical - Cell line xenograft Actionable In a preclinical study, Tanibirumab (TTAC-0001) inhibited angiogenesis and tumor growth in human cell line xenograft models of colorectal cancer (PMID: 26325365). 26325365
KDR positive Advanced Solid Tumor predicted - sensitive Tanibirumab Phase I Actionable In a Phase I trial, Tanibirumab treatment demonstrated manageable toxicity and preliminary efficacy, resulted in increased circulating Kdr (Vegfr2), Vegf and Pigf, and stable disease in 61% (11/18) of patients with refractory solid tumors (PMID: 28391576; NCT01660360). 28391576
Unknown unknown glioblastoma multiforme not applicable Tanibirumab Preclinical - Cell line xenograft Actionable In a preclinical study, Tanibirumab (TTAC-0001) inhibited angiogenesis and tumor growth in human glioblastoma cell line xenograft models (PMID: 26325365). 26325365
Clinical Trial Phase Therapies Title Recruitment Status